Transient visual loss and delayed resolution of vitreomacular traction after intravitreal ocriplasmin
نویسندگان
چکیده
Vitreomacular traction and vitreomacular traction with macular hole are conditions associated with visual disturbance and decreased visual acuity. Recent studies have demonstrated that ocriplasmin is effective and safe in specific patient groups with vitreomacular traction, and hence is recommended as a treatment option. We present here a case report of a patient treated with intravitreal ocriplasmin associated with severe loss of vision and delayed resolution of vitreomacular traction. This report highlights that it is important for patients to be made fully aware of the risks of intravitreal ocriplasmin and the prognosis for visual improvement.
منابع مشابه
Initial experience with ocriplasmin in the treatment of vitreomacular traction.
This study aimed to report the clinical and structural outcomes of intravitreal ocriplasmin in the treatment of vitreomacular interface disorders in two tertiary centers in Brazil. A retrospective study was performed by reviewing medical records and spectral domain optical coherence tomography (SD-OCT) findings of seven patients who were treated with a single ocriplasmin injection. A total of 5...
متن کاملVision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography.
IMPORTANCE Clinical trials indicate that visual impairment is significantly greater in patients receiving ocriplasmin than placebo. The mechanism of this symptom has not been explained. We report a patient with persistent darkening of her vision after intravitreal ocriplasmin and describe ancillary testing findings that may yield insights into the effects of ocriplasmin and the cause of this sy...
متن کاملIncomplete Vitreomacular Traction Release Using Intravitreal Ocriplasmin
PURPOSE To report the clinical course of our first 7 consecutive patients treated with intravitreal ocriplasmin (Jetrea(®)). METHODS Retrospective case series of the first 7 patients treated with ocriplasmin between January and December 2013 at an academic tertiary care center. RESULTS The average age was 78.4 years (range: 63-92). Five patients were pseudophakic and 2 patients were phakic ...
متن کاملPneumo-Enzymatic Vitreolysis for Resistant Vitreomacular Traction
Aim: Case report describing a patient with resistant vitreomacular traction (VMT) treated with an intravitreal injection of a potentially safer, lower dose of ocriplasmin and with a residual intravitreal gas bubble from pneumatic vitreolysis. Case Report: An 88-year-old man with symptomatic vitreomacular traction (VMT) was observed for 4 weeks without spontaneous release. Pneumatic vitreolysis ...
متن کاملLooking at ocriplasmin as a new option in eye disease.
Vitreomacular traction (VMT) syndrome and macular hole (MH) are disease processes that are caused by anomalous separation of the vitreous from the macula. Until now, management of these conditions has involved vitreoretinal surgery. Clinical trials have shown that a single intravitreal microplasmin (ocriplasmin) injection can induce separation of the vitreous from the macular surface and thereb...
متن کامل